Fluid retention is characteristic of veno-occlusive disease (VOD). We hypothesized that plasma brain natriuretic peptide (BNP), a neurohormone secreted in response to volume expansion, may be associated with VOD after hematopoietic stem cell transplantation (HSCT). BNP was measured before and weekly after HSCT in 46 recipients. Sixteen patients developed VOD. BNP concentrations were similar before and on day 0 in patients with and without VOD, but were significantly higher on day 7 and later in those with VOD. Patients with VOD had significantly higher peak BNP concentrations before engraftment than those without VOD (median, 634.4 versus 80.9 pg ml
Introduction
Hepatic veno-occlusive disease (VOD) is an important complication of hematopoietic stem cell transplantation (HSCT). It usually occurs within the first three weeks and is characterized by painful hepatomegaly, jaundice, ascites, fluid retention and weight gain. VOD develops in less than 10% to as high as 60% of patients after HSCT and ranges in severity from mild and reversible disease to a severe syndrome associated with multi-organ failure and death. [1] [2] [3] However, reliable diagnostic and prognostic laboratory parameters for VOD have not been established, and making treatment decisions is still difficult.
Brain natriuretic peptide (BNP) is a 32-amino-acid neurohormone synthesized in the ventricular myocardium, and secreted in response to volume expansion and pressure overload. BNP shows natriuretic and vasodilatory effects, and counteracts the effects of the renin-angiotensinogenangiotensin system. 4 Plasma BNP concentration is elevated in patients with left ventricular (LV) dysfunction, and correlates with both severity of symptoms and prognosis. [4] [5] [6] [7] Previous studies indicated plasma BNP concentration can be increased in HSCT recipients, and its monitoring is useful for early detection of patients at risk for cardiac dysfunction after HSCT. [8] [9] [10] [11] As fluid retention is usually the first sign and characteristic feature of VOD, we hypothesized that plasma BNP is elevated in patients with VOD, is associated with its severity and serves as a prognostic marker after HSCT. Therefore, we performed a retrospective analysis on whether plasma BNP has an association with VOD and early mortality in allogeneic HSCT recipients.
Methods

Patients
This retrospective analysis included 46 consecutive adult patients who underwent allogeneic HSCT at our institution between February 2008 and June 2009. Two patients who received second allogeneic HSCT for graft failure, and one patient with missing data during this time period, were excluded from this analysis. This study was performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of the University of Tokyo Hospital.
Transplantation procedure
Myeloablative conditioning regimen consisted of CY plus fractionated TBI with or without other agents (etoposide or cytarabine), whereas non-myeloablative conditioning regimen mainly consisted of fludarabine and melphalan with or without low-dose TBI. Patients with non-malignant diseases received CY-based regimen. Patients were offered non-myeloablative conditioning regimen because they were ineligible for conventional HSCT due to old age (455 years), preexisting significant medical problem or prior HSCT. Prophylaxis for GVHD was performed with calcineurin inhibitors (cyclosporine or tacrolimus) with short-term methotrexate. HLA matching for donor selection was based on serologic typing for HLA-A and HLA-B antigens, and molecular typing for HLA-DRB1 allele. Prophylaxis against bacterial infection was performed with fluoroquinolones, fungal infection with fluconazole or itraconazole, herpes simplex virus infection with acyclovir and Pneumocystis jiroveci infection with sulfamethoxazole/ trimethoprim. Disease morphology was determined according to the World Health Organization classification of tumors of hematopoietic and lymphoid tissues. 12 Standardrisk diseases included acute leukemia in first or second remission; chronic myeloid leukemia in first or second chronic phase; myelodysplasia-refractory cytopenia with unilineage dysplasia; refractory anemia with ring sideroblasts; and refractory cytopenia with multilineage dysplasia, chemosensitive lymphoma and non-malignant diseases. All the other conditions were classified as high-risk diseases.
BNP and left ventricular ejection function
Plasma BNP concentration (normal range, o18.4 pg ml À1 ) was measured once before transplantation for routine workup and weekly after transplantation, using fluorescence enzyme immunoassay at our hospital. Evaluation of LV ejection fraction (LVEF) by ultrasound cardiography was performed within 3 months before transplantation. When patients showed signs and symptoms of fluid retention after transplantation, cardiac function was re-evaluated by a cardiac team. As differential diagnosis of plasma BNP elevation, primary heart disease (for example, ischemic heart disease or heart valve disease), sepsis, acute renal failure, acute GVHD, VOD and the toxicity of conditioning regimen were considered. 13 Sepsis was defined as a systemic inflammatory response syndrome in the presence of a clinically or microbiologically documented infection using the American College of Chest Physicians/Society of Critical Care Medicine guideline.
14 Acute renal failure was defined as a doubling of baseline serum creatinine in accordance with the previous report. 15 Acute GVHD was diagnosed and graded according to standard guideline. 16 Veno-occlusive disease The diagnosis of VOD was based on the Seattle criteriadevelopment of at least two of the three following clinical features within 20 days after transplantation: hyperbilirubinemia with serum total bilirubin 42 mg dl À1 ; hepatomegaly with right upper quadrant pain and weight gain 42% from baseline body weight due to fluid retention. 17 The severity of VOD was defined according to the established criteria: mild for clinically manifested VOD that resolved without intervention; moderate for VOD that required treatment but resolved completely and severe for VOD that caused death or progressed to multi-organ failure. 17, 18 Multi-organ failure was defined as either oxygen requirement with an oxygen saturation of o90% on air and/or ventilator dependence; renal insufficiency (doubling of baseline creatinine level and/or dependence of dialysis) and/or encephalopathy. To be VOD-related, multi-organ failure had to be diagnosed within 28 days of diagnosis of VOD. Prophylaxis for VOD was performed using ursodeoxycholic acid for patients with preexisting liver dysfunctions. Once VOD was diagnosed, standard supportive care measures were adopted, such as restriction of daily sodium and fluid intake, diuretics and hematological support.
Statistical methods
Plasma BNP concentrations obtained during the consecutive 1-week periods (the indicated day ±3 days) were used for the analysis and presented as median and interquartile ranges. Statistical comparison of plasma BNP concentrations between patient groups was performed using Mann-Whitney U-test. The cut-off values of plasma BNP concentration were determined by receiver operating characteristic curve analysis. To assess the association between plasma BNP elevation and VOD, logistic regression model was performed.
Landmark analysis at day 7 was performed for overall survival (OS) according to plasma BNP concentration. The Kaplan-Meier method was used for estimating OS, and the log-rank test was used to assess differences in OS between patient groups. As most patients with severe VOD died within 100 days after HSCT, 17 OS was analyzed at day 100. Other covariates considered in univariate analyses were age (o50 years versus X50years), disease status at transplantation (standard-risk versus high-risk), donor type (HLAmatched versus HLA-mismatched), conditioning regimen (myeloablative versus non-myeloablative), GVHD prophylaxis (cyclosporine and methotrexate versus tacrolimus and methotrexate) and history of previous transplantation (0 versus X1). The association between plasma BNP concentration and OS was evaluated in multivariate analysis with the use of Cox proportional-hazards regression. The variables with a P-value less than 0.1 in univariate analyses were included in multivariate analysis. All P-values are twosided, with a type-I error rate fixed at 0.05. Statistical analyses were performed with the R 2.9.0 software (The R Foundation for Statistical Computing, 2009).
previous transplantation and echocardiographic parameters are shown in Table 1 . There was no case with cardiac or cardiovascular disease except for one patient with heart valve disease. The median follow-up period for survivors after HSCT was 167 days (range, 101-441 days). A total of nine (19.6%) patients died before day 100 and 16 (34.8%) patients developed VOD (mild to moderate in eight and severe in eight) between 1 and 15 days (median, 9 days) after transplantation.
Plasma BNP concentration and VOD Plasma BNP concentrations were similar before and on day 0 between patients with and without VOD, but significantly increased on day 7 and later in those with VOD ( Figure 1 ). Peak plasma BNP concentrations in the pre-engraftment period in patients with VOD were significantly more elevated as compared with those without VOD (median, 634.4 pg ml À1 (interquartile range, 443.8-2768.9 pg ml À1 ) versus 80.9 pg ml À1 (48.5-125.1 pg ml À1 ); P ¼ 0.01). Comparison across the severity of VOD showed that peak plasma BNP concentrations before engraftment were significantly higher in patients with severe VOD than in those with mild-to-moderate VOD (3001.0 pg ml À1 (1937.3-3899.5 pg ml À1 ) versus 471.3 pg ml À1 (443.8-600.9 pg ml
As most patients presented VOD around day 7, we determined the optimal cut-off value to predict VOD, using peak plasma BNP concentration before day 7. Receiver operating characteristic curve analysis showed that a BNP cut-off value of X130 pg ml À1 could effectively differentiate patients with VOD from those without VOD, with a sensitivity of 81.3% and a specificity of 93.3% (Figure 2 ). In addition, a BNP cut-off value of X180 pg ml À1 could distinguish patients with severe VOD from those with mild-to-moderate VOD or without VOD, with a sensitivity of 75.0% and a specificity of 81.6%.
Plasma BNP concentration and other transplant-related complications As plasma BNP concentration can increase in various diseases, such as congestive heart failure, [4] [5] [6] [7] renal failure 19, 20 and sepsis, [21] [22] [23] [24] we conducted logistic regression analysis to evaluate the impact of VOD on elevated plasma BNP, using other transplant-related complications as covariates. As there was no case with acute GVHD in the pre-engraftment period, sepsis (yes versus no), acute renal failure (yes versus no), pre-transplant LVEF (X67 versus o67%) and conditioning regimen (myeloablative versus non-myeloablative) were considered as possible contributing factors to the elevation of plasma BNP concentration. In this analysis, VOD was the only significant variable associated with the elevation of plasma BNP concentration (X130 pg ml À1 ) (odds ratio, 50.1 (95% confidence interval (95% CI), 5.2-478.4); Po0.01) ( Table 2) .
After transplantation, eight patients showed clinically significant fluid retention before engraftment, and were re-evaluated by expert cardiologists. All of them had VOD and their peak BNP concentrations before engraftment ranged from 701.3 to 10390.9 pg ml
À1
. Cardiac performance was normal (LVEF X50%) in five patients and moderately Plasma BNP predicts VOD and mortality after HSCT K Kataoka et al deteriorated (LVEF 30-50%) in three patients when they had peak plasma BNP concentrations. As, in these three patients with decreased LVEF, primary heart disease was excluded through comprehensive non-invasive evaluation, the cause of impaired cardiac function was considered to be myocardial dysfunction due to critically ill status (that is, stress cardiomyopathy). 25 Plasma BNP concentration and early mortality To investigate the prognostic value of BNP, peak BNP concentration in the pre-engraftment period was compared between survivors and non-survivors at day 100. In patients who died within 100 days, peak plasma BNP concentrations were significantly higher than those who survived longer than 100 days (2536.7 pg ml À1 (290.7-3890.7 pg ml À1 ) versus 115.1 pg ml À1 (54.5-226.0 pg ml À1 ); P ¼ 0.04). As peak plasma BNP concentration before day 7 (X180 pg ml À1 ) could effectively differentiate patients with severe VOD from those with mild-to-moderate VOD, we used this cut-off value in survival analyses. Landmark analysis at day 7 showed that survival at day 100 in patients with peak plasma BNP concentration of X180 pg ml À1 (n ¼ 13) was significantly worse than that in patients with peak plasma BNP concentration o180 pg ml À1 (n ¼ 33) (53.8% (95% CI, 32.6-89.1%) versus 91.0% (95% CI, 81.6-100.0%); Po0.01) (Figure 3) . In univariate analyses, HLA-mismatched transplantation predicted significantly worse survival (P ¼ 0.04), whereas other variables did not show any significant association with survival at day 100. In multivariate analysis, including plasma BNP elevation at day 7 (X180 pg ml À1 ) and HLAmismatched transplantation as covariates, plasma BNP elevation before day 7 was the only significant predictor of inferior survival at day 100 (hazard ratio, 5.3 (95% CI, 1.1-24.3); P ¼ 0.03) ( Table 3) . Figure 2 Receiver operating characteristic curve analysis for determining the optimal cut-off value of plasma BNP concentration to predict the occurrence of VOD in 46 patients undergoing allogeneic HSCT. To determine the optimal cut-off value to predict the occurrence of VOD, we constructed a receiver operating characteristic curve using peak plasma BNP concentration before day 7. The receiver operating characteristic curve analysis showed that a BNP cut-off value of X130 pg ml À1 (arrow) could effectively differentiate patients with VOD from those without VOD, with a sensitivity of 81.3% and a specificity of 93.3% (area under the curve, 0.904). BNP, brain natriuretic peptide; HSCT, hematopoietic stem cell transplantation; VOD, veno-occlusive disease. Table 2 Factors associated with the elevation of plasma BNP concentration before day 7 in 46 patients undergoing allogeneic HSCT: logistic regression model ) before day 7, using occurrence of venoocclusive disease, sepsis, acute renal failure, pre-transplant left ventricular ejection fraction and conditioning regimen as covariates.
Discussion
We found that plasma BNP concentration was elevated in patients with VOD, and associated with the severity of VOD, irrespective of the coexistence of sepsis and renal failure. In addition, peak plasma BNP concentration before day 7 was an independent predictor of worse survival at day 100. Considering the dismal prognosis in severe VOD, and emerging new therapies for this disorder such as defibrotide, 18, 26 it is important to identify patients with poor prognosis for making treatment decisions. Furthermore, as histological confirmation of VOD is difficult, there is a need for reliable diagnostic markers of this disease. Although a prognostic regression model was proposed on the basis of serum bilirubin and weight gain, 27 it is not used widely because of the absence of validation for various conditioning regimens. 1 Our findings suggested, as plasma BNP is simple, inexpensive and widely available in clinical practice, it can become a good prognostic indicator of VOD.
There are some explanations for increased plasma BNP value in patients with VOD. Cardiac wall stretch is considered to be the main mechanical stimulus for BNP production and secretion. As it occurs under conditions characterized by fluid retention and volume expansion, elevation of plasma BNP concentration may be secondary to this phenomenon in patients with VOD. In contrast, levels of various cytokines, coagulation factors and markers of endothelial cell damage have been shown to be elevated in VOD. [1] [2] [3] Among them, several mediators, such as TNF-a, IL-1 and endothelin-1, can induce the production and secretion of BNP. [28] [29] [30] Thus, there is a possibility that BNP is involved in the pathogenesis of VOD. In addition, accumulating evidence suggests that transient LV systolic dysfunction in the absence of coronary artery disease can occur in patients with acute medical illness, especially those treated in intensive care units. 21, 25 As three patients with VOD showed decreased LV function with no evidence of acute coronary syndrome in the follow-up echocardiography, there was a possibility that, in severe cases, an unidentified mechanism related to VOD induces the myocardial depression, which leads to the elevation of plasma BNP concentration. However, it is unknown whether BNP elevation is the cause or consequence of VOD. Plasma levels of natriuretic peptide hormones may be increased in various clinical diseases, such as cardiovascular disease, [4] [5] [6] [7] renal failure, 19, 20 liver cirrhosis 31 and sepsis. [21] [22] [23] [24] Considering patients without VOD showed a moderately increased plasma BNP concentration in the pre-engraftment period, there may be several contributing factors to the elevation of plasma BNP concentration. However, it is important to recognize that the degree of plasma BNP elevation in patients with VOD can be considerably higher than in other disorders. 21, 32 Hence, although plasma BNP is not a VOD-specific marker, highly elevated concentration of this neurohormone may be unique to VOD.
In this analysis, increased peak plasma BNP concentration before day 7 was associated with decreased survival at in 46 patients undergoing allogeneic HSCT. Survival at day 100 in patients with peak plasma BNP concentration of X180 pg ml À1 (n ¼ 13) was significantly worse than patients with peak BNP concentration o180 pg ml À1 (n ¼ 33) (53.8 versus 91.0%; Po0.01). BNP, brain natriuretic peptide; HSCT, hematopoietic stem cell transplantation. The log-rank test was used to assess differences in overall survival at day 100 between patient groups. b Cox proportional-hazards regression model was used in multivariate analysis, using variables with P-value less than 0.1 in univariate analyses as covariates.
day 100. As previous reports showed that a variety of serious conditions can cause elevation of plasma BNP concentration, [4] [5] [6] [7] [19] [20] [21] [22] [23] [24] 31 the negative prognostic impact of elevated plasma BNP might reflect the critically ill status caused by these diseases. However, as occurrence of VOD was the only factor that had an independent association with elevation of plasma BNP concentration before day 7, plasma BNP concentration may serve as a prognostic indicator of VOD.
This study had the typical limitation of a retrospective cohort study. As this study was performed in a single center, and the sample size was small, large-scale prospective multicenter studies are warranted. As diagnosis of VOD was based on clinical manifestations, further reports with histological confirmation would be helpful to confirm these findings.
In conclusion, we showed plasma BNP concentration to be elevated in patients with VOD, and correlated with the severity of VOD and early mortality after HSCT. These findings suggested that plasma BNP may represent a diagnostic and prognostic marker of VOD after allogeneic HSCT and could offer a valuable tool toward therapeutic interventions.
